Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555248 | 0.87 | WNT1 (0.37) | ALDH1A1CNR1WNT1GSK3BDYRK1A | |
| SCHEMBL9210619 | 0.84 | GABRA1 (0.36) | ALDH1A1WNT1GSK3BDYRK1ASMN1; SMN2 | |
| SCHEMBL12629021 | 0.81 | ALDH1A1 (0.39) | ALDH1A1WNT1GSK3BDYRK1ACDK9 | |
| SCHEMBL9216887 | 0.81 | WNT1 (0.40) | ALDH1A1WNT1GSK3BDYRK1ASMN1; SMN2 | |
| SCHEMBL9212767 | 0.79 | SLC6A9 (0.47) | ALDH1A1CXCR4DRD2 | |
| SCHEMBL18915176 | 0.79 | MAOA (0.35) | ALDH1A1WNT1GSK3BDYRK1ACDK9 | |
| SCHEMBL12629144 | 0.78 | KMT2A (0.47) | ALDH1A1WNT1GSK3BDYRK1ASMN1; SMN2 | |
| SCHEMBL18915038 | 0.77 | CDK9 (0.37) | ALDH1A1CDK9 | |
| SCHEMBL38655181 | 0.77 | EGFR (0.37) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3470166 | 0.76 | PLA2G10 (0.41) | ALDH1A1WNT1GSK3BDYRK1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208139-B2 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | SCHERING AG (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-06-02 | — | — | US | disclosed |
| US-6855309-B2 | For use in diagnostics and therapy | SCHERING, AG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030232017-A1 | For use in diagnostics and therapy | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | US | disclosed |
| US-6576222-B2 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-10 | — | — | US | disclosed |
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | SCHERING AG (DE) | 2002-06-06 | — | — | US | disclosed |
| US-6299859-B1 | ADMINISTERING CONTRAST AGENT COMPRISING CASCADE POLYMER COMPLEX AND NUCLEAR MAGNETIC RESONANCE IMAGING TISSUES FOR DIFFERENTIATING ISCHEMIC AND/OR INFRACTED TISSUE FROM NORMAL TISSUES | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-10-09 | — | — | US | disclosed |
| US-6183724-B1 | ADMINISTERING A CONTRAST AGENT FOR NMR IMAGING THE BLOOD VESSELS, SIZE LARGE ENOUGH FOR ITS RETENTION IN THE BLOOD VESSELS AND SMALL ENOUGH FOR ITS EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-06 | — | — | US | disclosed |
| US-6054117-A | NUCLEAR MAGNETIC RESONANCE CONTRAST MEDIA FOR DIAGNOSTICS AND THERAPY; PHYSIOLOGICALLY ACCEPTABLE EXCRETION | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-04-25 | — | — | US | disclosed |
| US-5911971-A | NMR CONTRAST MEDIA WHICH CAN MARK THE VASAL SPACE (BLOOD POOL AGENT); UNIFORM AND HIGH ENOUGH MOLECULAR WEIGHT TO BE RETAINED IN BLOOD VESSEL BUT SMALL ENOUGH TO BE ELIMINATED BY THE KIDNEY; POLYAMINOAMIDES; MACROMOLECULES | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-06-15 | — | — | US | disclosed |
| US-5650136-A | Cascade polymer bound complexing compounds, their complexes and conjugates, processes for their production, and pharmaceutical agents containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-07-22 | — | — | US | disclosed |
| US-5403572-A | Macrocyclic polyaza compounds containing 5 or 6 membered rings, process for producing them and pharmaceutical media containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-04-04 | — | — | US | disclosed |
| EP-0352218-B1 | Macrocyclic polyaza compounds containing rings with 5 or 6 members, methods for their preparation and pharmaceutical compositions containing same | SCHERING AG (DE) | 1995-02-22 | — | — | EP | disclosed |
| US-5334371-A | Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-08-02 | — | — | US | disclosed |
| EP-0430863-A2 | Complexe builders bonded to sterwise prepared polymers, their complexes and conjugates, process for their preparation and pharmaceutical agents containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068037-A1 | Complex stability and specificity; NMR contrast media as diagnostic aid for localization of vascular disease | CAD, APOB, SLC7A1 | ALDH1A1 4841/4885CXCR4 2803/4885CNR1 2375/4885 |
| US-20030232017-A1 | For use in diagnostics and therapy | TFPI, BCAT2, OAT | ALDH1A1 3976/4885CXCR4 2936/4885CNR1 4424/4885 |
| US-20050118105-A1 | Conducting nuclear spin tomography on a patient who has been administered a cascade polymer complex having complex-forming ligands for imaging of inflammation and/or tumors in the brain | FABP7, SLC1A3, SLC43A1 | ALDH1A1 4833/4885CXCR4 3461/4885CNR1 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.